Matthew Arroyo, MD
Internal Medicine · Charlotte, NCNPI 1538131818
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,848 and has fallen 96.4% since, to $66 in 2025. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$721
- AbbVie$556
- Lundbeck LLC$354
- Sunovion Pharmaceuticals Inc.$204
- Teva Pharmaceuticals USA, Inc.$201
- Avanir Pharmaceuticals, Inc.$198
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,566 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 940 | $16,454 |
| Donepezil Hcl | 802 | $7,388 |
| Mirtazapine | 129 | $2,220 |
| Quetiapine Fumarate | 154 | $2,051 |
| Escitalopram Oxalate | 120 | $1,127 |
| Ziprasidone Hcl | 23 | $766 |
| Atorvastatin Calcium | 46 | $599 |
| Buspirone Hcl | 111 | $582 |
| Levetiracetam | 19 | $565 |
| Divalproex Sodium | 18 | $563 |
| Latanoprost | 18 | $485 |
| Cefadroxil | 20 | $318 |
| Sertraline Hcl | 79 | $308 |
| Azelastine Hcl | 12 | $302 |
| Carvedilol | 12 | $211 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Charlotte
- Saad UsmaniCharlotte$551K
- Marc JohnsonCharlotte$342K
- Maithili ChitnavisCharlotte$267K
- Jonathan SchwartzCharlotte$193K
- Perry RoyCharlotte$135K
- Benjamin BrooksCharlotte$91K
- Mark SchwartzCharlotte$80K
- Thomas WalshCharlotte$64K
- Lisa BellanfonteCharlotte$45K
- Nirmish ShahDurham$862K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.